Mounjaro on the NHS in 2026: Eligibility, Cost, and Where to Find It

The 2024-2025 weight-loss-injection boom changed how the UK talks about obesity. Wegovy (semaglutide) arrived first, Mounjaro (tirzepatide) followed, and Saxenda quietly slipped down the ranking. By spring 2026, demand for these injections has run far ahead of NHS supply, and most people who want them are still paying privately, usually through a community pharmacy or an online doctor service.

NICE recommended tirzepatide for managing obesity on the NHS in its 2024 technology appraisal, with a phased rollout that pushes most eligible patients into specialist weight-management services over three years. That means even patients who qualify on paper often wait, and some never get an appointment at all. This guide covers who actually qualifies in 2026, what the NHS route looks like, what the private market charges, and the safety questions to ask before you start.

What Mounjaro (tirzepatide) actually is

Tirzepatide is a once-weekly injection that activates two gut-hormone receptors at the same time: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). That dual mechanism is what distinguishes it from Wegovy and Ozempic, which act on GLP-1 alone.

The MHRA originally licensed tirzepatide for type 2 diabetes, sold under the brand name Mounjaro. A separate licence for chronic weight management followed, covering adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related health problem. NICE then issued a technology appraisal recommending tirzepatide for NHS use in obesity, subject to specialist weight-management-service oversight.

In clinical trials reported in the New England Journal of Medicine (the SURMOUNT-1 study), participants on the highest tirzepatide dose lost an average of about 20 per cent of body weight over 72 weeks. That is the headline figure that drove demand, and it sits alongside a side-effect profile dominated by nausea and other gastrointestinal effects, especially during the dose-escalation phase.

NHS eligibility in 2026

The headline NICE criteria are tight. To be considered for tirzepatide on the NHS for weight management, you need a body mass index (BMI) of at least 35 kg per square metre and at least one weight-related health condition (commonly type 2 diabetes, sleep apnoea, cardiovascular disease, or hypertension). A BMI of 30 to 34.9 may qualify if you meet stricter conditions, including coming from a population at higher cardiometabolic risk at lower BMI (for example, people of South Asian, Chinese, Black African or Black Caribbean ancestry, where NICE applies a lower BMI threshold).

Above the eligibility bar sits a second filter: local rationing. NICE has been clear that the rollout will be phased over three years to protect specialist services. Each Integrated Care Board in England (and each Health Board in Scotland, Wales and Northern Ireland) sets its own annual cap and prioritisation criteria. In practice, that means two people with identical BMI and the same comorbidity may get different answers depending on postcode.

Honest framing: even if you qualify on paper, your GP may say no. That is not a failure of the GP, it is the rationing model working as designed. The next step in that case is the private route or, in some areas, the digital weight-management programmes that NHS England has commissioned alongside the injection.

What the NHS route actually involves

The NHS pathway starts with a GP appointment. Your GP will check BMI, comorbidities, mental-health history, and current medicines, then refer you to a Tier 3 or Tier 4 specialist weight-management service. Those services typically combine dietitian input, psychological support, and physical-activity guidance alongside the medicine itself.

Once you are accepted, the injection is prescribed through the specialist service or by your GP under a shared-care arrangement. Dispensing happens at a community pharmacy. NHS prescription charges in England are £9.90 per item in 2026 unless you are exempt. In Scotland, Wales and Northern Ireland, NHS prescriptions are free, so the dispensed medicine costs nothing.

The catch is access. NHS waiting lists for specialist weight-management services run into months in most areas, and longer in some. The NICE phased rollout caps how many patients each service can start each year. If your area has hit its annual cap, you wait.

Why most people pay privately

Long waits, tight rationing, and a tested-and-licensed medicine that delivers visible results. The result, predictably, is a fast growing private market. UK community pharmacies (independents and chains alike), online doctor services, and dedicated weight-loss clinics now between them prescribe and dispense the bulk of tirzepatide used outside the NHS.

The private route is faster and looser on eligibility (most providers will prescribe at BMI 30, or BMI 27 with a comorbidity, in line with the MHRA licence rather than the NICE NHS threshold). It is also expensive: £150 to £250 a month is the typical envelope in 2026, before any consultation fee.

Private Mounjaro pricing (approximate, mid-2026)

All figures below are typical and approximate as of mid-2026. Prices rise as the dose escalates, so a stable patient on 10 mg or 15 mg will usually pay more than a new patient on 2.5 mg.

• Online doctor services (for example Pharmacy2U, Boots Online Doctor, Numan, Manual, LloydsDirect, Asda Online Doctor): roughly £150 to £250 a month. Consultation is usually built into the price. Some include free pen needles and sharps bins; others charge separately.
• In-pharmacy private consultations: roughly £130 to £200 a month, often plus a one-off £30 to £50 initial consultation fee for the first visit. The face-to-face assessment is the main difference versus an online service.
• Independent community pharmacies offering it: variable, often £140 to £220 a month. The pricing spread tracks local property costs and prescriber availability rather than any centrally negotiated rate.
• Bundle discounts: 3-month and 6-month bundles are now standard across most providers and typically shave 5 to 15 per cent off the monthly headline price.

What to ask before you start

Mounjaro is a serious medicine with a clear safety profile and a clear dose-escalation schedule. Any prescriber, NHS or private, should walk you through the following before your first dose:

• Dose schedule: starts at 2.5 mg once weekly, steps up every four weeks through 5 mg, 7.5 mg, 10 mg, 12.5 mg, and a maximum of 15 mg. Not every patient reaches the top dose; many stabilise at 7.5 mg or 10 mg.
• Early side-effects: nausea, vomiting, constipation, diarrhoea, reflux, fatigue. These are most common during dose increases and usually settle within a week or two at each step.
• Serious risks to know about: pancreatitis, gallbladder problems, kidney effects from severe vomiting or dehydration, and a labelled contraindication in people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
• What happens if you stop: most patients regain a meaningful share of the weight within a year of stopping unless lifestyle changes have stuck. Plan the stop, do not just drop the injection.
• How to store and inject: the KwikPen is pre-filled and refrigerated. Once in use it stays at room temperature for a defined window; check the patient leaflet for the current figure.

Where to find it locally

A growing share of UK community pharmacies now offer a private weight-management service alongside their NHS work, especially in larger cities. The fastest way to find one in your area is to phone two or three local pharmacies, ask whether they have an independent prescriber who runs a weight-management clinic, and compare the headline monthly cost.

You can use the Find a Pharmacy search to locate open pharmacies near you, then ring ahead. We do not currently tag pharmacies by private-service offering, but independent pharmacies in larger cities are the most likely to run a clinic.

• Pharmacies open in London
• Pharmacies open in Manchester
• Pharmacies open in Edinburgh

Red flags when buying privately

The MHRA and the General Pharmaceutical Council (GPhC) have published repeated warnings on illegal tirzepatide supply through social media, messaging apps, and unverified websites. The shortlist of red flags below is a useful filter:

• No clinical assessment of any kind before purchase. A legitimate provider takes a full medical history, asks about other medicines, and confirms BMI.
• No BMI check, or willingness to prescribe at a BMI well below the MHRA licence (the licence covers BMI 30 and above, or BMI 27 with a comorbidity).
• No named prescriber, no GPhC registration number on the website, and no UK address.
• Prices that are dramatically below the market range, or cash-only / cryptocurrency-only payment. Genuine UK pharmacies accept card and operate from a verifiable trading address.
• No follow-up review, no plan for dose escalation, and no monitoring of side-effects or weight outcome.

If a service looks wrong, check the pharmacy on the GPhC online register before paying anything. Counterfeit pens have been seized in the UK throughout 2024 and 2025.

What is coming next

Wegovy supply has been intermittent through 2025 and is expected to stabilise through 2026 as Novo Nordisk expands manufacturing. On the horizon, Eli Lilly’s retatrutide (a triple-receptor agonist) is in late-stage trials and has shown larger weight-loss effects than tirzepatide in early data, though it is still some way from a UK licence.

On the NHS side, the next NICE review and the ICB cap reviews for the 2027-28 commissioning year are expected to be published in late summer 2026. Whether the rollout speeds up or stays at current pace will largely be determined there.

Frequently asked questions